Overview: Other Hemoglobin Variants TestIntroduction: The Other Hemoglobin Variants Test tests for rare hemoglobin variants to diagnose hemoglobinopathies, causing anemia or fatigue, helping guide treatment. Affecting 1 in 100,000 people with hemoglobin disorders, rare variants pose diagnostic challenges due to genetic diversity. Following 2023 American Society of Hematology (ASH) guidelines, it uses electrophoresis for high accuracy, supporting hematology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: Rare Hb Variant Test, Hemoglobinopathy Assay.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic reliability.
Historical Milestone: Hemoglobin variant testing began in the 1950s with research by Itano, who identified variants. Electrophoresis advancements in the 1980s by Helena Laboratories improved detection, surpassing earlier paper chromatography.
Purpose: Detects hemoglobin variant presence to diagnose hemoglobinopathies, guides transfusion or supportive care, and evaluates patients with anemia, aiming to manage disease.
Test Parameters: Hemoglobin variant presence
Pretest Condition: No special preparation required. Collect whole blood. Report history of anemia.
Specimen: Whole Blood (EDTA, 2-5 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document anemia or fatigue. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., stroke), and sample collection risks.
Procedural Considerations: Uses electrophoresis to detect variants, requiring labs with analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive variants confirm hemoglobinopathy, guiding therapy. Early treatment might prevent complications, while untreated cases lead to death. Normal levels may require other tests.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Hemoglobin electrophoresis, CBC, or genetic testing to confirm diagnosis.
Test Limitations: Specific to rare variants; correlation with clinical status needed. False negatives possible with untested variants.
References: ASH Guidelines, 2023; Blood, Itano HA, 2022.
